These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 14723327)

  • 1. Evaluation of the efficacy of bitter gourd (momordica charantia) as an oral hypoglycemic agent--a randomized controlled clinical trial.
    John AJ; Cherian R; Subhash HS; Cherian AM
    Indian J Physiol Pharmacol; 2003 Jul; 47(3):363-5. PubMed ID: 14723327
    [No Abstract]   [Full Text] [Related]  

  • 2. Hypoglycemic effect of bitter melon compared with metformin in newly diagnosed type 2 diabetes patients.
    Fuangchan A; Sonthisombat P; Seubnukarn T; Chanouan R; Chotchaisuwat P; Sirigulsatien V; Ingkaninan K; Plianbangchang P; Haines ST
    J Ethnopharmacol; 2011 Mar; 134(2):422-8. PubMed ID: 21211558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum sialic acid changes in non-insulin-dependant diabetes mellitus (NIDDM) patients following bitter melon (Momordica charantia) and rosiglitazone (Avandia) treatment.
    Inayat-ur-Rahman ; Malik SA; Bashir M; Khan R; Iqbal M
    Phytomedicine; 2009 May; 16(5):401-5. PubMed ID: 19362455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phytochemical determination and extraction of Momordica charantia fruit and its hypoglycemic potentiation of oral hypoglycemic drugs in diabetes mellitus (NIDDM).
    Tongia A; Tongia SK; Dave M
    Indian J Physiol Pharmacol; 2004 Apr; 48(2):241-4. PubMed ID: 15521566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antidiabetic activity of Momordica charantia seeds on streptozotocin induced diabetic rats.
    Sekar DS; Sivagnanam K; Subramanian S
    Pharmazie; 2005 May; 60(5):383-7. PubMed ID: 15918591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoglycemic efficacy and safety of Momordica charantia (bitter melon) in patients with type 2 diabetes mellitus.
    Kim SK; Jung J; Jung JH; Yoon N; Kang SS; Roh GS; Hahm JR
    Complement Ther Med; 2020 Aug; 52():102524. PubMed ID: 32951763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Momordica charantia for type 2 diabetes mellitus.
    Ooi CP; Yassin Z; Hamid TA
    Cochrane Database Syst Rev; 2012 Aug; (8):CD007845. PubMed ID: 22895968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Momordica charantia and type 2 diabetes: from in vitro to human studies.
    Habicht SD; Ludwig C; Yang RY; Krawinkel MB
    Curr Diabetes Rev; 2014 Jan; 10(1):48-60. PubMed ID: 24295371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Momordica charantia for type 2 diabetes mellitus.
    Ooi CP; Yassin Z; Hamid TA
    Cochrane Database Syst Rev; 2010 Feb; (2):CD007845. PubMed ID: 20166099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Advances in the study of Momordica charantia L].
    Liu X; Li S; Feng C; Yan D
    Zhong Yao Cai; 2002 Mar; 25(3):211-3. PubMed ID: 14748342
    [No Abstract]   [Full Text] [Related]  

  • 11. Momordica charantia L. lowers elevated glycaemia in type 2 diabetes mellitus patients: Systematic review and meta-analysis.
    Peter EL; Kasali FM; Deyno S; Mtewa A; Nagendrappa PB; Tolo CU; Ogwang PE; Sesaazi D
    J Ethnopharmacol; 2019 Mar; 231():311-324. PubMed ID: 30385422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-diabetic potentials of Momordica charantia and Andrographis paniculata and their effects on estrous cyclicity of alloxan-induced diabetic rats.
    Reyes BA; Bautista ND; Tanquilut NC; Anunciado RV; Leung AB; Sanchez GC; Magtoto RL; Castronuevo P; Tsukamura H; Maeda KI
    J Ethnopharmacol; 2006 Apr; 105(1-2):196-200. PubMed ID: 16298503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antioxidant properties of Momordica Charantia (bitter gourd) seeds on Streptozotocin induced diabetic rats.
    Sathishsekar D; Subramanian S
    Asia Pac J Clin Nutr; 2005; 14(2):153-8. PubMed ID: 15927932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bitter gourd reduces elevated fasting plasma glucose levels in an intervention study among prediabetics in Tanzania.
    Krawinkel MB; Ludwig C; Swai ME; Yang RY; Chun KP; Habicht SD
    J Ethnopharmacol; 2018 Apr; 216():1-7. PubMed ID: 29339109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ACCORD Trial and control of blood glucose level in type 2 diabetes mellitus: time to challenge conventional wisdom.
    Havas S
    Arch Intern Med; 2009 Jan; 169(2):150-4. PubMed ID: 19171811
    [No Abstract]   [Full Text] [Related]  

  • 16. Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan.
    Bakiner O; Ertorer ME; Bozkirli E; Tutuncu NB; Demirag NG
    Acta Diabetol; 2009 Mar; 46(1):63-5. PubMed ID: 18825302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bitter gourd (Momordica Charantia): A dietary approach to hyperglycemia.
    Krawinkel MB; Keding GB
    Nutr Rev; 2006 Jul; 64(7 Pt 1):331-7. PubMed ID: 16910221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive therapy of type 2 diabetes (ACCORD trial) (OCTOBER 2008).
    Najman DM
    Cleve Clin J Med; 2009 Feb; 76(2):83; author reply 83-4. PubMed ID: 19188472
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy.
    Goldberg RB; Fonseca VA; Truitt KE; Jones MR
    Arch Intern Med; 2008 Jul; 168(14):1531-40. PubMed ID: 18663165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of mulberry leaf extract on the blood glucose and breath hydrogen response to ingestion of 75 g sucrose by type 2 diabetic and control subjects.
    Mudra M; Ercan-Fang N; Zhong L; Furne J; Levitt M
    Diabetes Care; 2007 May; 30(5):1272-4. PubMed ID: 17303787
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.